Lipoprotein(a): From molecules to therapeutics

American Journal of Therapeutics

Volumn 17, Issue 3, 2010, Pages 263-273

  Bermúdez, Valmore ^a   Arráiz, Nailet ^a   Aparicio, Daniel ^a   Rojas, Edward ^a   Gotera, Daniela ^a   Guerra, Xavier ^a   Canelón, Roger ^a   Faría, Judith ^a   Sorell, Luis ^b   Amell, Anilsa ^a   Reyna, Nadia ^a   Cabrera, Mayela ^a   Mengual, Edgardo ^a   Cano, Raquel ^a   Cano, Clímaco ^a   Velasco, Manuel ^c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Atherogenesis; Cardiovascular disease; Hyperlipoproteinemia(a); Lipoprotein(a); Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ANDROGEN; APOB 43724392; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; ATORVASTATIN; CARNITINE; CASEIN; ESTROGEN; ETOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PLASMINOGEN; POLYUNSATURATED FATTY ACID; SIMVASTATIN; SOMATOMEDIN C; SOYBEAN PROTEIN; STEROID HORMONE; SYNTHETIC PEPTIDE; TESTOSTERONE; UNCLASSIFIED DRUG;

ATHEROGENESIS; AUTOSOMAL INHERITANCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DISULFIDE BOND; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; FLUSHING; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERURICEMIA; LONG TERM CARE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PRURITUS; REVIEW; SEX DIFFERENCE; SIDE EFFECT; STRUCTURAL HOMOLOGY; THROMBOGENESIS;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77952470697     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e00bf1     Document Type: Review

References (103)

1. Berg K. A new serum type system in man, the Lp System. Acta Pathol Microbiol Scand. 1963;59:369-382.
2. Mohr J, Berg K. Genetics of the Lp serum types: Associations and Linkage Relations. Acta Genet Stat Med. 1963;13:343-348.
3. Berg K, Wendt GG. The Lp system-manufacturing of antiserum, testing methods, results. Humangenetik. 1964;1;24-30.
4. Berg K, Boman H, Torsvik H, et al. Allotypy of high density lipoprotein of rabbit serum. Proc Natl Acad Sci USA. 1971;68:905-908.
5. Gedde-Dahl Jun, Berg K. Linkage in man: the Inv and the Lp serum type systems. Nature. 1965;208:1126.
6. Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the national heart, lung, and blood institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Special Rep Clin Chem. 2003;49:1785-1796.
7. Berglund L, Ramakrishnan R. Lipoprotein (a). An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24:2226.
8. Lippi G, Guidi G. Lipoprotein (a): from ancestral benefit to a modern pathogen? Q J Med. 2000;93:75-84.
9. Becker L, Webb BA, Chitayat S, et al. A ligand-induced conformational change in apolipoprotein (a) enhances covalent Lp (a) formation. J Biol Chem. 2003;278:14074-14081.
10. Wang W, Dongsheng Hu, Lee ET, et al. Lipoprotein (a) in American Indians is low and not independently associated with cardiovascular disease: the Strong Heart Study. Ann Epidemiol. 2002;12:107-114.
11. Scanu AM. Lipoprotein (a): looking ahead. Nutr Metab Cardiovasc Dis. 2005;15:331-333.
12. Scanu AM. Lp (a) Lipoprotein-coping with Heterogeneity. N Engl J Med. 2003;349:2089-2090.
13. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels-The Framingham Offspring Study. Circulation. 1993;87:1135-1141.
14. Enas EA, Chacko V, Senthilkumar A, et al. Elevated lipoprotein (a) -a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon. 2006;52:5-50.
15. Marcovina SM, Kennedy H, Bittolo Bon G, et al. Fish intake, independent of apo (a) size, accounts for lower plasma lipoprotein (a) levels in Bantu fishermen of Tanzania-The Lugalawa Study. Arterioscler Thromb Vasc Biol. 1999;19:1250-1256.
16. Wang J, Boedeker J, Hobbs HH, et al. Determinants of human apolipoprotein [a] secretion from mouse hepatocyte cultures. J Lipid Res. 2001;42:60-69.
17. White AL, Lanfort RE. Cell surface assembly of lipoprotein (a) in primary cultures of baboon hepatocytes. J Biol Chem. 1994;269:28716-28723.
18. Bonen DK, Hausman AM, Hadjiagapiou C, et al. Expression of a recombinant apolipoprotein (a) in HepG2 cells. J Biol Chem. 1997;272:5659-5667.
19. Trieu VN, McConathy WJ. A two-step model for lipoprotein (a) formation. J Biol Chem. 1995;270:15471-15474.
20. Brunner C, Kraft HG, Utermann G, et al. Cys4057 of apolipoprotein (a) is essential for lipoprotein assembly. Proc Natl Acad Sci USA. 1993;90:11643-11647.
21. Cheesman EJ, Sharp RJ, Zlot CH, et al. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein (a). J Biol Chem. 2000;275:28195-28200.
22. Becker L, McLeod RS, Marcovina SM, et al. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein (a). J Biol Chem. 2001;276:36155-36162.
23. Liu CY, Broadhurst R, Marcovina SM, et al. Mutation of lysine residues in apolipoprotein B-100 causes defective lipoprotein[a] formation. J Lipid Res. 2004;45:63-70.
24. Sharp RJ, Perugini MA, Marcovina SM, et al. A synthetic peptide that inhibits lipoprotein (a) assembly. Thromb Vasc Biol. 2003;23:502-507.
25. Becker L, Cook PM, Wright TG, et al. Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein (a) Kringle IV types 6-8 to lipoprotein (a) assembly. J Biol Chem. 2004;279:2679-2688.
26. Koschinsky ML, Marcovina SM. Structure function relationships in apolipoprotein (a): insights into lipoprotein (a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15:167-174.
27. Jialal I. Evolving lipoprotein risk factors: lipoprotein (a) and oxidized low-density lipoprotein. Clin Chem. 1998;44:1827-1832.
28. White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein (a) folding in the endoplasmic reticulum. J Biol Chem. 1997;272:5048-5055.
29. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein (a) concentrations with apolipoprotein (a) isoform size is not due to differences in Lp (a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758-2763.
30. Frank S, Kostner GM. The role of apo- (a) kringle-IVs in the assembly of lipoprotein- (a). Protein Eng. 1997;10:291-298.
31. White AL, Guerra B, Wang J, et al. Presecretory degradation of apolipoprotein[a] is mediated by the proteasome pathway. J Lipid Res. 1999;40:275-286.
32. Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46:2681-2691.
33. Scanu AM, Nakajima K, Edelstein C. Apoliprotein (a): structure and biology. Front Biosci. 2001;6:546-554.
34. Kostner GM, Hrzenjak A, Frank S, et al. The catabolism of lipoprotein (a). Int Congress Ser. 2004;1262:554-557.
35. Niemeier A, Willnow T, Dieplinger H, et al. Identification of megalin/gp330 as a receptor for lipoprotein (a) in vitro. Arterioscler Thromb Vasc Biol. 1999;19:552-561.
36. Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp (a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170-2181.
37. Mooser V, Marcovina SM, White AL, et al. Kringlecontaining fragments of apolipoprotein (a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414-2424.
38. Gonbert S, Saint-Jore H, Giral P, et al. Molecular analysis of apo (a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern. Arterioscler Thromb Vasc Biol. 2001;21:1353-1358.
39. Lamanuzzi LB, Mtairag M, Pepe G, et al. Neutrophils stimulated by apolipoprotein (a) generate fragments that are stronger inhibitors of plasmin formation than apo (a). Thromb Haemost. 2004;92:1066-1075.
40. Scanu AM, Edelstein C. Learning about the structure and biology of human lipoprotein [a] through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res. 1997;38:2193-2206.
41. Kostner KM, Kostner GM. Lipoprotein (a): still an enigma?. Curr Opin Lipidol. 2002;13:391-396.
42. Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301-2306.
43. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein (a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol. 1998;32:2035-2042.
44. Marcovina SM, Koschinsky ML. Lipoprotein (a) concentration and apolipoprotein (a) size: a synergistic role in advanced atherosclerosis? Circulation 1999;10:1151-1153.
45. Nowak-Göttl U, Debus O, Findeisen M, et al. Lipoprotein (a): its role in childhood thromboembolism. Pediatrics. 1997;99:1-11.
46. Kronenberg F, Kronenberg MF, Kiechlv S, et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation. 1999;10:1154-1160.
47. von Depka M, Nowak-Göttl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96:3364-3368.
48. Seman LJ, De Luca C, Jenner JL, et al. Lipoprotein (a) - cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem. 1999;45:1039-1046.
49. Dati F, Tate JR, Marcovina SM, et al. First WHO/IFCC International Reference reagent for lipoprotein (a) for immunoassay-Lp (a) SRM 2B. Clin Chem Lab Med. 2004;42:670-676.
50. Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein (a) size predicts mortality in end-stage renal disease. The CHOICE Study. Circulation. 2002;106:2812.
51. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein (a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998;18:1393-1399.
52. Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein (a): critical domains in apolipoprotein (A) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278(26):23260-23269.
53. Ichikawa T, Unoki H, Sun H, et al. Lipoprotein (a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo (a) transgenic rabbits. Am J Pathol. 2002;160:227-236.
54. Syrovets T, Thillet J, Chapman MJ, et al. Lipoprotein (a) is a potent chemoattractant for human peripheral monocytes. Blood. 1997;90:2027-2036.
55. Poon M, Zhang X, Dunsky KG, et al. Apolipoprotein (a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation. 1997;96:2514-2519.
56. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis. Circulation. 1999;100:1154-1160.
57. Yamada S, Morishita R, Nakamura S, et al. Development of antibody against epitope of lipoprotein (a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein (a). Circulation. 2000;102:1639-1644.
58. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein (a): evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem. 2001;276:46864-46869.
59. Romero FI, Khamashta MA, Hughes GR. Lipoprotein (a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus. 2000;9:206-209.
60. Scanu AM. Lipoprotein (a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep. 2003;5:106-113.
61. Su W, Campos H, Judge H, et al. Metabolism of Apo (a) and ApoB100 of lipoprotein (a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab. 1998;83:3267-3276.
62. Bermúdez V, Arraiz N, Rojas E, et al. Abnormally high lipoprotein (a) levels in African-American communities from Venezuela faced to other African-descending populations: are ethnic origins related?. Rev Latinoamericana Hipertensión. 2008;3:66-72.
63. Obisesan TO, Aliyu MH, Adediran AS, et al. Correlates of serum lipoprotein (A) in children and adolescents in the United States. The Third National Health Nutrition and Examination Survey (NHANES-III). Lipids Health Dis. 2004;3:39.
64. Tavridou A, Unwin N, Bhopal R, et al. Predictors of lipoprotein (a) levels in a European and South Asian population in the Newcastle Heart Project. Eur J Clin Invest. 2003;33:686-692.
65. Nasiff-Hadad A, Núñez-Suárez N, Cordero-Rojas R, et al. Concentraciones séricas de lipoproteína (a) en pacientes cubanos dislipémicos. Clin Invest Arterioscl. 2003;15:233-238.
66. Ariyo AA, Thach Ch, Tracy R. Lp (a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108-2115.
67. Bermúdez V, Cabrera M, Mengual E, et al. Lipoproteína (a) en una población urbana de Venezuela: evidencia de que su incremento por deprivación estrogénica es transitorio. Anales Med Intern. 2007;24:324-327.
68. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46-57.
69. Olascoaga A, Ventura J, Tavella N, et al. Lipoproteína (a) y riesgo Aterogénico en pacientes en Hemodiálisis Crónica. Rev Mex Patol Clin. 2001;48:161-165.
70. Solfrizzi V, Panza F, D'Introno A, et al. Lipoprotein (a), apolipoprotein E genotype, and risk of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:732-736. (Pubitemid 34557014)
71. Emanuele E, Peros E, Tomaino C, et al. Relation of apolipoprotein (a) size to Alzheimer's disease and vascular dementia. Dementia Geriatric Cognitive Disord. 2004;18:189-196.
72. Min WK, Lee JO, Huh JW. Relation between lipoprotein (a) concentrations in patients with acute phase response and risk analysis for coronary heart disease. Clin Chem. 1997;43:1891-1895.
73. Laron Z, Wang XL. Clinical perspective growth hormone, lipoprotein (a) and cardiovascular disease. Eur Heart J. 1998;19:204-206.
74. Meinertz H, Nilausen K, Hilden J. Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein (a) markedly. Arterioscl Thromb Vasc Biol. 2002;22:312-316.
75. Nilausen K, Meinertz H. Lipoprotein (a) and dietary proteins: casein lowers lipoprotein (a) concentrations as compared with soy protein. Am J Clin Nutr. 1999;69:419-425.
76. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
77. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697-705.
78. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1:195-202.
79. Davidson MH. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003;5:418-422.
80. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
81. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
82. Pan J, Van JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein (a) in diabetes. Metabolism. 2002;51:1120-1127.
83. Kagawa A, Azuma H, Akaike M, et al. Aspirin reduces apolipoprotein (a) (Apo (a)) production in human hepatocytes by suppression of apo (a) gene transcription. J Biol Chem. 1999;274:34111-34115.
84. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein (a) in patients with atherosclerotic diseases. Clin Chem. 2002;48:1454-1459.
85. Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia-a pilot study involving serial sampling. Curr Med Res Opin. 2001;16:269-275.
86. Kaur K, Rai J, Sharma G, et al. An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia. Curr Ther Res. 2004;65:445-469.
87. Ramires JA, Manzur AP, Soloimene MC, et al. Effect of gemfibrozil versus lovastatin on increased serum lipoprotein (a) levels of patients with hypercholesterolemia. Int J Cardiol. 1995;48:115-120.
88. Nestel P, Simons L, Barter P, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by base line lipids, apo E genotype, lipoprotein (a) and insulin. Atherosclerosis. 1997;129:231-239.
89. Nolte W, Rädisch C, Armstrong VW, et al. The effect of recombinant human GH replacement therapy on lipoprotein (a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. Eur J Endocrinol. 1997;137:459-466.
90. Tao R, Acquati F, Marcovina SM, et al. Human growth hormone increases apo (a) expression in transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:2439-2447.
91. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a), and risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
92. Takeshita M, Saito S, Katsuragi Y, et al. Combination of plant sterols and diacylglycerol oil lowers serum cholesterol and lipoprotein (a) concentrations in postmenopausal women with mild to moderate hypercholesterolemia. Eur e-J Clin Nutr Metab. 2007;2:4-11.
93. Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004;38:253-259.
94. Seed M, O'Connor B, Perombelon N, et al. The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis. 1993;101:61-68.
95. O'Kane MJ, Trinick TR, Tynan MB, et al. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol. 1992;33:451-453.
96. Sposito A, Mansur A, Maranhão R, et al. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. Braz J Med Biol Res. 2001;34:177-182.
97. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp (a). Nutr Metab Cardiovasc Dis. 2000;10:247-251.
98. Derosa G, Cicero AF, Gaddi A, et al. The effect of darnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther. 2003;25:1429-1439.
99. Ruiz JR, Mesa J, Mingorance I, et al. Deportes con alto grado de estrés físico afectan negativamente al perfil lipídico plasmático. Rev Esp Cardiol. 2004;57:499-506.
100. Mackinnon LT, Hubinger LM. Effects of exercise on lipoprotein (a). Sports Med. 1999;28:11-24.
101. Boraita A. La práctica deportiva mejora el perfil lipídico plasmático, pero ¿a cualquier intensidad? Rev Esp Cardiol. 2004;57:495-498.
102. Sharp RJ, Perugini MA, Marcovina SM, et al. A synthetic peptide that inhibits lipoprotein (a) assembly. Thromb Vasc Biol. 2003;23:502-507.
103. Sharp RJ, Perugini MA, Marcovina SM, et al. Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein (a) assembly. J Lipid Res. 2004;45:2227-2234.